HOTH

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Hoth Therapeutics awarded U.S. patent for HT-KIT cancer treatment platformMay 26, 2026
• Hoth Therapeutics secured authorization in Spain for its Phase 2a HT-001 trial with encouraging interim efficacy dataMay 6, 2026
• Hoth reported data showing GDNF improved liver fat metabolism and outperformed semaglutideApr 14, 2026
• Hoth received a Chinese patent for its cancer cell-targeting technologyMar 31, 2026
• Hoth Therapeutics reported positive PK, safety, and clinical activity data for HT-001 showing increased exposure and minimal systemic absorption in patients with EGFR-related skin toxicitiesMar 24, 2026